Author:
Liu Jieqiong,Jiang Wen,Mao Kai,An Yi,Su Fengxi,Kim Betty Y. S.,Liu Qiang,Jacobs Lisa K.
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Howlader N NA, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). (2013) SEER Cancer Statistics Review, 1975–2010. National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975_2010/ , based on November 2012 SEER data submission, posted to the SEER web site, April 2013
2. Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program. Oncologist 12(1):20–37. doi: 10.1634/theoncologist.12-1-20
3. Curtis RE, Boice JD Jr, Shriner DA, Hankey BF, Fraumeni JF Jr (1996) Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88(12):832–834
4. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW et al (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343(8895):448–452
5. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA, Ford L (1999) Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91(19):1654–1662
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献